NCT07144085 is a Phase 1 clinical trial of 68Ga-FXX489 in Tumor, sponsored by Yi Tian.

Who is sponsoring NCT07144085?

NCT07144085 is sponsored by Yi Tian.

What drugs are being tested in NCT07144085?

Interventions in NCT07144085: 68Ga-FXX489, Positron Emission Tomography (PET) imaging, Gallium-68 labelled (68Ga-) FAP-2286.

What condition does NCT07144085 study?

NCT07144085 studies Tumor, Metastatic Cancer.

Is NCT07144085 still recruiting?

NCT07144085 is currently recruiting now. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT07144085

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.

Recruiting now Phase 1 Last updated 3 April 2026

What this trial tests

Phase 1 trial testing 68Ga-FXX489 in Tumor in 30 participants. Currently enrolling.

Timeline

11 September 2025

Primary endpoint
30 July 2027

30 July 2027

Quick facts

Lead sponsor	Yi Tian
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	11 September 2025
Primary completion	30 July 2027
Estimated completion	30 July 2027
Sites	1 location across China

Drugs / interventions tested

68Ga-FXX489 — full drug profile →
Positron Emission Tomography (PET) imaging
Gallium-68 labelled (68Ga-) FAP-2286 — full drug profile →

Conditions studied

Tumor — all drugs for Tumor →
Metastatic Cancer — all drugs for Metastatic Cancer →

Sponsor

Yi Tian — full company profile →

Who can join

Adults 18 to 80, any sex, with Tumor or Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A new radiotracer, 68Ga-FXX489 (NNS309), has been developed for tracking fibroblast activation protein (FAP) and visualizing the tumor stroma. The purpose of the study is to explore the diagnostic value of 68Ga-FXX489 (NNS309) PET/CT imaging in oncological diseases, to assess its safety, imaging characteristics, and biodistribution after administration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Tumor

Currently open trials in the same condition.

NCT07399652 — Artificial Intelligence-Guided Detection of Blood Vessels to Enhance Safety in Third-Space Endoscopic Procedures · NA · recruiting
NCT07382752 — Decoupling Immunotherapy Toxicity and Cancer Response · recruiting
NCT07464132 — Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases · Phase 1, PHASE2 · recruiting
NCT07147465 — Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for On · recruiting
NCT07000864 — A Study of Live Tumor Fragments of Surgical Resections · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07144085 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yi Tian
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07144085.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing